pharma Β· TTR-mediated Amyloidosis Β· Hypertension Β· ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands patent portfolio β 379 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
Alnylam Netherlands patents
379 pharmaceutical patents indexed for Alnylam Netherlands. 4 expire within 24 months.
Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months β use filters for patent-cliff planning.
Patent portfolio
-
US 8334373
Nuclease resistant double-stranded ribonucleic acid
granted -
US 8324366
Compositions and methods for delivering RNAI using lipoproteins
granted -
US 8324368
GNAQ targeted dsRNA compositions and methods for inhibiting expression
granted -
US 8318693
Compositions and methods for inhibiting expression of mutant EGFR gene
granted -
US 8293719
iRNA agents targeting VEGF
granted -
US 8288525
Compositions and methods for inhibiting expression of CD45 gene
granted -
US 8273870
Compositions and methods for inhibiting expression of a mutant gene
granted -
US 8273869
Lipid formulated dsRNA targeting the PCSK9 gene
granted -
US 8273868
Compositions and methods for inhibiting viral replication
granted -
US 8268799
Compositions and methods for inhibiting expression of the HAMP gene
granted -
US 8263572
RNAi modulation of RSV and therapeutic uses thereof
granted -
US 8227188
Enhancement of influenza gene expression
granted -
US 8222222
Compositions and methods for inhibiting expression of the PCSK9 gene
granted -
US 8202980
Method and medicament for inhibiting the expression of a given gene
granted -
US 8188061
RNAi modulation of APOB and uses thereof
granted -
US 8183362
Method and medicament for inhibiting the expression of a given gene
granted -
US 8168776
Method for making a 21 nucleotide double stranded RNA chemically linked at one end
granted -
US 8168775
Compositions and methods for inhibiting expression of transthyretin
granted -
US 8163711
Compositions and methods for inhibiting expression of the HAMP gene
granted -
US 8158601
Lipid formulation
granted -
US 8158773
RNAi modulation of RSV and therapeutic uses thereof
granted -
US 8148344
Compositions and methods for mediating RNAi in vivo
granted -
US 8143390
Compositions and methods for inhibiting expression of anti-apoptotic genes
granted -
US 8119608
Method and medicament for inhibiting the expression of a given gene
granted -
US 8114981
Method and medicament for inhibiting the expression of a given gene
granted -
US 8114984
RNAi modulation of Aha and therapeutic uses thereof
granted -
US 8114851
Method and medicament for inhibiting the expression of a given gene
granted -
US 8110674
Therapeutic compositions
granted -
US 8106022
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 8101742
Method and medicament for inhibiting the expression of a given gene
granted -
US 8101584
Method and medicament for inhibiting the expression of a given gene
granted -
US 8080532
Compositions and methods for inhibiting expression of Huntingtin gene
granted -
US 8058257
Compositions and methods for inhibiting expression of a gene from the JC virus
granted -
US 8034376
Lipid containing formulations
granted -
US 8034793
RNAi modulation of MLL-AF4 and uses thereof
granted -
US 8017762
Modified iRNA agents
granted -
US 8017763
Chemically modified oligonucleotides
granted -
US 8013136
Oligonucleotides comprising a non-phosphate backbone linkage
granted -
US 8003619
Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
granted -
US 7994307
RNAi modulation of the BCR-ABL fusion gene and uses thereof
granted -
US 7994309
Compositions and methods for inhibiting expression of a mutant gene
granted -
US 7985581
Multiple RNA polymerase III promoter expression constructs
granted -
US 7981869
RNAi modulation of RSV and therapeutic uses thereof
granted -
US 7956177
dsRNA compositions and methods for treating HPV infection
granted -
US 7947659
iRNA agents targeting VEGF
granted -
US 7928217
Nuclease resistant double-stranded ribonucleic acid
granted -
US 7919473
IRNA agents targeting VEGF
granted -
US 7906484
Complex for transferring an anionic substance into a cell
granted
Frequently asked questions
How many patents does Alnylam Netherlands have?
379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Alnylam Netherlands patents expire?
4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.